KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Operating Expenses for 11 consecutive years, with $267.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 160.39% year-over-year to $267.7 million, compared with a TTM value of $681.9 million through Dec 2025, up 110.86%, and an annual FY2025 reading of $681.9 million, up 110.86% over the prior year.
  • Other Operating Expenses was $267.7 million for Q4 2025 at Alnylam Pharmaceuticals, up from $200.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $267.7 million in Q4 2025 and bottomed at $31.1 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $81.2 million, with a median of $67.3 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses decreased 19.56% in 2024, then soared 160.39% in 2025.
  • Year by year, Other Operating Expenses stood at $37.7 million in 2021, then skyrocketed by 36.11% to $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then grew by 19.75% to $102.8 million in 2024, then skyrocketed by 160.39% to $267.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for ALNY at $267.7 million in Q4 2025, $200.2 million in Q3 2025, and $143.0 million in Q2 2025.